Search

PRX-07034

Barbexaclone

Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.

Odanacatib

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

Hydracarbazine

Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

Atractylodes japonica root oil

It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.

Nirogacestat

Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

Rilapladib

Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

Cirazoline

Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain. … Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2.

Cimicoxib

If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.